Posted by Michael Wonder on 18 Feb 2020
Horizon Therapeutics announces U.S. FDA approval of new dosage form for Procysbi (cysteamine bitartrate) delayed-release oral granules
18 February 2020 - Oral granules in packets provide an additional, tear-open option for people living with cystinosis.
Horizon Therapeutics announced today that the U.S. FDA has approved Procysbi (cysteamine bitartrate) delayed-release oral granules in packets for adults and children one year of age and older living with nephropathic cystinosis.
This new dosage form provides another option for people living with cystinosis, in addition to the currently available Procysbi capsules.
